Skip to main content
Clinical Trials/TCTR20190702004
TCTR20190702004
Recruiting
Phase 2

Correlation of Body Composition Measured by Bioelectrical Impedance Analysis and Hematologic Adverse Events in Early-stage Breast Cancer Patients Receiving Chemotherapy

Siriraj Research Fund0 sites150 target enrollmentJuly 2, 2019

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Patients with stage I&#45
Sponsor
Siriraj Research Fund
Enrollment
150
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 2, 2019
End Date
March 1, 2020
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Siriraj Research Fund

Eligibility Criteria

Inclusion Criteria

  • 1\. Newly diagnosed with stage I, II or III breast cancer
  • 2\. Planned to receive (neo)adjuvant chemotherapy consisting of one of the following regimens: cyclophosphamide/doxorubicin (AC), docetaxel/ cyclophosphamide (TC), AC followed by paclitaxel or docetaxel, 5FU/epirubicin/cyclophosphamide (FEC) followed by docetaxel
  • 3\. Signed informed consent

Exclusion Criteria

  • 1\. Patients with automated implantable cardioverter\-defibrillator (AICD), permanent pacemaker or other metallic device
  • 2\. Patients known to have pleural effusion, ascites or generalized edema

Outcomes

Primary Outcomes

Not specified

Similar Trials